SOPHiA DDM™ Platform will bring
next-generation sequencing in-house and help further
research on hematologic malignancies
BOSTON and ROLLE, Switzerland, July 7, 2023
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
software company and a leader in data-driven
medicine, today announced Centre Hospitalier de Bastia is live
on the SOPHiA DDM™ Platform. Centre Hospitalier de Bastia, a
general hospital located in the city of Bastia, on the French
island of Corsica, is using the SOPHiA DDM™ Platform to introduce
in-house next-generation sequencing (NGS), which will support their
clinical oncology research and facilitate deeper insights into
hematologic malignancies.
Hematologic cancers such as leukemia, lymphoma, and myeloma
begin in the cells of the immune system or in blood-forming tissue,
such as the bone marrow.[1] These types of cancers, also
called blood cancers, represent the fourth most frequent cancer
type in the developed world[2] and can move fast.
The SOPHiA DDM™ Platform is a cloud-based platform that
uses Artificial Intelligence (AI) with patented technologies to
synthesize next-generation sequencing (NGS) data; this is key when
categorizing disease-associated mutations. The SOPHiA DDM™
Platform will enable Centre Hospitalier de Bastia to build in-house
expertise, further their molecular testing capabilities, and help
to accelerate their research on hematologic malignancies and
potentially other cancer types.
By using the SOPHiA DDM™ Platform, Centre Hospitalier de Bastia
will be able to synchronize its testing and reporting capabilities
across the four units of the Pole technique et Medico-Technique
center and the public health department; this will support
expedited analysis and better equip researchers, as they work
to practice data-driven medicine.
"Next-generation sequencing has become the gold standard in
genomic testing, specifically as it relates to fast-moving and
sometimes complex cancers like hematologic malignancies," said
Kevin Puylaert, VP of Business Development and Marketing,
SOPHiA GENETICS. "By using the
SOPHiA DDM™ Platform, Centre Hospitalier de Bastia is
enhancing their research capabilities and connecting with
world-class institutions globally, making precision medicine a
reality in Corsica."
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
1 https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hematologic-cancer
2 https://gco.iarc.fr/today/fact-sheets-cancers accessed
on May 19th, 2021.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/centre-hospitalier-de-bastia-is-live-on-sophia-genetics-301871492.html
SOURCE SOPHiA GENETICS